Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!

Autor: Nguyen AA; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America., Habiballah SB; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America., Platt CD; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America., Geha RS; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America., Chou JS; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America., McDonald DR; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America. Electronic address: Douglas.McDonald@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2020 Jul; Vol. 216, pp. 108459. Date of Electronic Publication: 2020 May 11.
DOI: 10.1016/j.clim.2020.108459
Abstrakt: The COVID-19 pandemic is one of the greatest infectious challenges in recent history. Presently, few treatment options exist and the availability of effective vaccines is at least one year away. There is an urgent need to find currently available, effective therapies in the treatment of patients with COVID-19 infection. In this review, we compare and contrast the use of intravenous immunoglobulin and hyperimmune globulin in the treatment of COVID-19 infection.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: